2012
Stent thrombosis: insights on outcomes, predictors and impact of dual antiplatelet therapy interruption from the SPIRIT II, SPIRIT III, SPIRIT IV and COMPARE trials.
Kedhi E, Stone G, Kereiakes D, Serruys P, Parise H, Fahy M, Simonton C, Sudhir K, Sood P, Smits P. Stent thrombosis: insights on outcomes, predictors and impact of dual antiplatelet therapy interruption from the SPIRIT II, SPIRIT III, SPIRIT IV and COMPARE trials. EuroIntervention 2012, 8: 599-606. PMID: 22995087, DOI: 10.4244/eijv8i5a92.Peer-Reviewed Original ResearchConceptsDAPT discontinuationCardiac deathSPIRIT IIST ratesDual antiplatelet therapy discontinuationDual antiplatelet therapy interruptionSPIRIT IIIAntiplatelet therapy discontinuationAntiplatelet therapy interruptionLarge pooled analysisRandomised clinical trialsTwo-year ratePatient-level databaseLog-rank testPES cohortTherapy discontinuationTherapy interruptionRandomised trialsStent thrombosisPaclitaxel-eluting stent deploymentPooled analysisClinical trialsDiscontinuationStent deploymentComposite rate
2011
Predictors of death or myocardial infarction, ischaemic-driven revascularisation, and major adverse cardiovascular events following everolimus-eluting or paclitaxel-eluting stent deployment: pooled analysis from the SPIRIT II, III, IV and COMPARE trials.
Kereiakes D, Smits P, Kedhi E, Parise H, Fahy M, Serruys P, Stone G. Predictors of death or myocardial infarction, ischaemic-driven revascularisation, and major adverse cardiovascular events following everolimus-eluting or paclitaxel-eluting stent deployment: pooled analysis from the SPIRIT II, III, IV and COMPARE trials. EuroIntervention 2011, 7: 74-83. PMID: 21550906, DOI: 10.4244/eijv7i1a14.Peer-Reviewed Original ResearchConceptsMajor adverse cardiovascular eventsAdverse cardiovascular eventsPaclitaxel-eluting stentsMyocardial infarctionIndependent predictorsID-TLRID-TVRCardiac deathCardiovascular eventsSPIRIT IIStent deploymentDrug-eluting stent deploymentPredictors of deathAdverse clinical outcomesCoronary artery diseaseSuperior clinical efficacyIschaemia-driven revascularisationNumber of lesionsArtery diseaseCoronary stentingClinical outcomesClinical efficacyAdverse outcomesPaclitaxel-eluting stent deploymentClinical trialsMULTIVARIABLE PREDICTORS OF CLINICAL RESTENOSIS, CARDIAC DEATH OR MYOCARDIAL INFARCTION TO 2 YEARS FOLLOWING EVEROLIMUS OR PACLITAXEL DRUG-ELUTING STENT DEPLOYMENT: THE SPIRIT II, III, IV AND COMPARE TRIAL EXPERIENCE
Kereiakes D, Smits P, Kedhi E, Parise H, Fahy M, Serruys P, Stone G. MULTIVARIABLE PREDICTORS OF CLINICAL RESTENOSIS, CARDIAC DEATH OR MYOCARDIAL INFARCTION TO 2 YEARS FOLLOWING EVEROLIMUS OR PACLITAXEL DRUG-ELUTING STENT DEPLOYMENT: THE SPIRIT II, III, IV AND COMPARE TRIAL EXPERIENCE. Journal Of The American College Of Cardiology 2011, 57: e1622. DOI: 10.1016/s0735-1097(11)61622-7.Peer-Reviewed Original ResearchEVEROLIMUS-ELUTING VS. PACLITAXEL-ELUTING STENTS. TWO-YEAR RESULTS FROM A PATIENT-LEVEL POOLED ANALYSIS FROM THE SPIRIT II, III, IV AND COMPARE RANDOMIZED TRIALS
Kedhi E, Smits P, Serruys P, Kereiakes D, Parise H, Fahy M, Stone G. EVEROLIMUS-ELUTING VS. PACLITAXEL-ELUTING STENTS. TWO-YEAR RESULTS FROM A PATIENT-LEVEL POOLED ANALYSIS FROM THE SPIRIT II, III, IV AND COMPARE RANDOMIZED TRIALS. Journal Of The American College Of Cardiology 2011, 57: e1824. DOI: 10.1016/s0735-1097(11)61824-x.Peer-Reviewed Original Research